{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:59:22Z","timestamp":1794488362010,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40265-023-01928-y","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T06:01:32Z","timestamp":1691560892000},"page":"1315-1321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Ritlecitinib: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"1928_CR1","unstructured":"Pfizer Inc. LITFULO\u2122 (ritlecitinib) capsules, for oral use: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215830s000lbl.pdf. Accessed 26 Jul 2023."},{"key":"1928_CR2","unstructured":"Pfizer. FDA approves Pfizer\u2019s LITFULO\u2122 (ritlecitinib) for adults and adolescents with severe alopecia areata [media release]. 23 June 2023. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and."},{"key":"1928_CR3","unstructured":"Pfizer Japan Inc. [Oral JAK3\/TEC family kinase inhibitor \"Litfulo\u00ae capsules 50mg (generic name: ritlecitinib tosylate)\" obtained manufacturing and marketing approval to meet the unmet needs of patients with alopecia areata] [media release]. 26 Jun 2023. https:\/\/www.pfizer.co.jp\/pfizer\/company\/press\/2023\/2023-06-26."},{"key":"1928_CR4","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Litfulo (ritlecitinib). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-litfulo_en.pdf. Accessed 26 Jul 2023."},{"issue":"6","key":"1928_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342.","journal-title":"ACS Chem Biol"},{"issue":"12","key":"1928_CR6","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"JB Telliez","year":"2016","unstructured":"Telliez JB, Dowty ME, Wang L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442\u201351.","journal-title":"ACS Chem Biol"},{"issue":"7","key":"1928_CR7","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/bcp.15695","volume":"89","author":"J Liu","year":"2023","unstructured":"Liu J, Solan R, Wolk R, et al. Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants. Br J Clin Pharmacol. 2023;89(7):2208\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"10387","key":"1928_CR8","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"3 Suppl.","key":"1928_CR9","doi-asserted-by":"publisher","first-page":"AB54","DOI":"10.1016\/j.jaad.2022.06.249","volume":"87","author":"N Mesinkovska","year":"2022","unstructured":"Mesinkovska N, Shapiro J, King B. Efficacy of the oral JAK3\/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial [abstract no. 33183]. J Am Acad Dermatol. 2022;87(3 Suppl.):AB54.","journal-title":"J Am Acad Dermatol"},{"key":"1928_CR10","doi-asserted-by":"crossref","unstructured":"King B, Mirmirani P, Lo Sicco K, et al. Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study [abstract no. LB1697]. In: First International Societies for Investigative Dermatology (ISID) Meeting. 2023.","DOI":"10.26226\/m.6437c1212973c5001292d126"},{"key":"1928_CR11","doi-asserted-by":"crossref","unstructured":"Piliang M, Soung J, King B, et al. Long-term efficacy of ritlecitinib up to month 24: integrated analysis of the ALLEGRO phase 2b\/3 and long-term phase 3 clinical studies in alopecia areata (AA) [abstract no. LB03]. In: 25th World Congress of Dermatology. 2023.","DOI":"10.1093\/bjd\/ljae365"},{"issue":"2","key":"1928_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1928_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","volume":"87","author":"E Peeva","year":"2022","unstructured":"Peeva E, Guttman-Yassky E, Banerjee A, et al. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol. 2022;87(2):390\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1928_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100156","volume":"2","author":"B King","year":"2022","unstructured":"King B, Guttman-Yassky E, Peeva E, et al. Safety and efficacy of ritlecitinib and brepocitinib in alopecia areata: results from the crossover open-label extension of the ALLEGRO phase 2a trial. JID Innov. 2022;2(6): 100156.","journal-title":"JID Innov."},{"issue":"2","key":"1928_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 2023;88(2):395\u2013403.","journal-title":"J Am Acad Dermatol"},{"key":"1928_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.029","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2022.12.029.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1928_CR17","doi-asserted-by":"crossref","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib for the treatment of alopecia areata (AA) from the phase 2 and phase 3 ALLEGRO clinical trial program [abstract no. T4 plus oral presentation]. In: European Hair Research Society Meeting. 2023.","DOI":"10.25251\/skin.7.supp.291"},{"key":"1928_CR18","doi-asserted-by":"crossref","unstructured":"Soung J, King B, Tziotzios C, et al. Integrated safety analysis of ritlecitinib in adolescent patients with alopecia areata from the randomized, placebo-controlled ALLEGRO phase 2b\/3 and ongoing open-label phase 3 ALLEGRO-LT studies [abstract no. 43117 plus poster]. In: American Academy of Dermatology Annual Meeting. 2023.","DOI":"10.1016\/j.jaad.2023.07.730"},{"key":"1928_CR19","unstructured":"Sinclair R, Lesiak A, Mehlis S, et al. Long-term safety and efficacy of ritlecitinib in patients with alopecia areata: interim results from the ALLEGRO-LT phase 3, open-label study [abstract no. FC27]. In: 25th World Congress of Dermatology. 2023."}],"updated-by":[{"DOI":"10.1007\/s40265-023-01956-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01928-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T18:38:08Z","timestamp":1729881488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":19,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01928-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"9 August 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-023-01956-8","URL":"https:\/\/doi.org\/10.1007\/s40265-023-01956-8","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}